Lpath Inc. (LPTN.OB) Reports Solid Clinical Trial Results for Investigational Drug ASONEP
Lpath Inc. focuses on lipidomics-based therapeutics for treating a wide range of human diseases. The company today announced positive data from its dose-escalation phase I clinical trial of the investigational drug ASONEP(TM) in cancer patients with various solid tumors. The study demonstrated that lymphocyte counts (the number of cells present in blood and lymphatic tissue) in the vascular space were reduced in a dose-related fashion, which led Lpath to achieve the objective established by Merck KGaA (Darmstadt, Germany), resulting in a $2 million payment per the license agreement with Merck KGaA. Results also show that the study met its primary…